BANKRUPTCY PLAYS

[I Like Bottom Fishing]

I am not sure what the hell is going on here but that sob MM nite has been messing with my head this dam stock should have pop a week ago imo! wee will see tomorrow i hope we got his ass cornered no wonder he was trying to take the osciq chart play down to 0.04, I think we are ready to go now these dam MM got me so confuse on this one, I don't know what the hell is going on! But here is the news dd research i did on osciq!

This Lupin Bio Company is out of India.

Thomson Reuters Lupin buys cholesterol-lowering drug for $38.61 mln

Tue Sep 29, 2009 10:06am IST

http://in.reuters.com/article/companyNews/idINBOM48848320090929

MUMBAI, Sept 29 (Reuters) - Drug maker Lupin Ltd (LUPN.BO: Quote, Profile, Research) said on Tuesday it bought U.S. rights for Antara, a cholesterol-lowering drug, for $38.61 million from U.S.-listed Oscient Pharamaceuticals OSCI.O.

The deal for Antara, or Fenofibrate capsules of 43 mg and 130 mg dosages, include product related assets and inclusive inventory, and was struck under US bankruptcy procedures, Lupin said in a statement.

The buy will help contribute to the revenue as well as profit, Vinita Gupta, group president and chief executive, Lupin, said in the statement.

The drug recorded a net sales of $70 million for 2008, the company said.

Earlier, Lupin had filed an ANDA for Fenofibrate capsules, but sold it to Dr. Reddy's Laboratories (REDY.BO: Quote, Profile, Research) prior to buying product rights from Oscient, the company added.

In July, US listed Oscient had filed for chapter 11 bankruptcy protection in the US court and sold its antibiotic drug Factive to a unit of Cornerstone Therapeutics Inc (CRTX.O: Quote, Profile, Research) for $5 million.

(Reporting by Ketan Bondre; Editing by Ramya Venugopal)

http://in.reuters.com/article/companyNews/idINBOM48848320090929

© Thomson Reuters 2009 All rights reserved


News for OSCIQ News Lupin Expands Branded Play --Announces Acquisition

Tuesday, September 29, 2009 4:45 PM

Scottrade.com
This email is compliments of Scottrade.com

News for 'OSCIQ' - (Lupin Expands Branded Play --Announces Acquisition of US Rights to ANTARA)

MUMBAI, India, Sept 29, 2009 /PRNewswire-FirstCall via COMTEX/ --
Pharmaceutical Major, Lupin Ltd. announced today the acquisition of US rights
for Antara(R) (Fenofibrate Capsules 43 mg and 130 mg). Lupin acquired the
product from Oscient Pharmaceuticals on September 25, 2009, under the procedures
of the U.S. Bankruptcy Court. Antara recorded net sales of US $ 70 million for
2008 (Source: IMS Dec 2008). Lupin paid $ 38.61 million for the product and
related assets inclusive of inventory.

Lupin had previously filed an ANDA for Fenofibrate Capsules 43 mg and 130 mg. On
September 21, 2009, prior to the acquisition of Antara(R), Lupin sold its ANDA
to Dr. Reddy's Laboratories. Lupin also settled and resolved the pending
litigation regarding the ANDA product.

Prior to the acquisition, Antara(R) was marketed by Oscient Pharmaceuticals.
Antara(R) has a strong brand equity with primary care physicians treating
patients for high LDL-C, Total-C, triglycerides, Apo-B and low HDL-C. The
Fenofibrate products market is $ 1.9 Billion for the last 12 months. Antara(R)
has 4.5% share of this market and grew 20 % in revenue this past year. Antara(R)
is prescribed for adjunct treatment of hypercholesterolemia (high blood
cholesterol) and hyper-triglyceridemia (high triglycerides) in combination with
diet.

The Antara acquisition enables Lupin to enter the primary care market with a
three product portfolio. Lupin's Suprax Tabs and Allernaze have strong potential
in primary care. Lupin will be more than doubling its sales force size in the
next 12 months to reach the key targets for the three products.

"We are very excited with our 2nd NDA acquisition within a span of 4 months. The
Antara(R) acquisition demonstrates Lupin's success in, and commitment to
building its brand franchise and equity in the US. It underlines Lupin's
differentiated strategy for the US market. Antara(R) is a step forward that will
help us strengthen and grow our brand business. Since Antara(R) is a previously
approved, commercial product, our sales and marketing efforts will commence
immediately and we are optimistic of it contributing positively to our topline
and bottomline in the coming quarters and years," said Vinita Gupta, Group
President & CEO, Lupin Pharmaceuticals Inc

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational
pharmaceutical company producing a wide range of quality, affordable generic and
branded formulations and APIs for the developed and developing markets of the
world. The Company today has significant market share in key markets in the
Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI,
Anti-Infectives and NSAIDs therapy segments, not to mention global leadership
positions in the Anti-TB and Cephalosporins. The Company's R&D endeavors have
resulted in significant progress in its NCE program. The Company's foray into
Advanced Drug Delivery Systems has resulted in the development of platform
technologies that are being used to develop value-added generic pharmaceuticals.

Our Drugs and products reach over 70 countries in the world. Today, Lupin has
the unique distinction of being the fastest growing top 10 Generics player in
the two largest pharmaceutical markets of the world -- The U.S. (ranked 9th by
prescriptions & growing at 92 %) and Japan (ranked 7th and growing at 23%). The
company is also the fastest growing, top 5 pharmaceutical player in India (ORG
IMS - March 2009) and the fastest growing Generic player in South Africa (ranked
6th and growing at over 30 % YoY - IMS)

For the financial year ended March 2009, Lupin's Consolidated Revenues and
Profit after Tax were Rs. 39,145 million and Rs. 5015 million respectively.

BSE: 500257 NSE: Lupin REUTERS: LUPN.BO BLOOMBERG: LPC IN

For further information contact:

Shamsher Gorawara

Head - Corporate Communications

Lupin Limited

[e-mail]

Mobile: [phone]

OR

Sonia Mansata

Text 100

[e-mail]

Mobile: [phone]

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act
of 1995:

This release contains forward-looking statements that involve known and unknown
risks, uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Many of these risks, uncertainties and
other factors include failure of clinical trials, delays in development,
registration and product approvals, changes in the competitive environment,
increased government control over pricing, fluctuations in the capital and
foreign exchange markets and the ability to maintain patent and other
intellectual property protection. The information presented in this release
represents management's expectations and intentions as of this date. Lupin
expressly disavows any obligation to update the information presented in this
release.

SOURCE Lupin Limited

www.prnewswire.com

Copyright (C) 2009 PR Newswire. All rights reserved

-0-

KEYWORD: India

INDUSTRY KEYWORD: PHA

MTC

HEA

SUBJECT CODE: TNM

Source: Comtext Market News